盐酸阿拉莫林(Anamorelin Hydrochloride) - 药物靶点：GHSR_在研适应症：恶病质，厌食症，非小细胞肺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

anamorelin、Anamorelin HCl、Anamorelin hydrochloride (JAN/USAN)

+ [10]

靶点

GHSR

作用机制

GHSR激动剂(促生长激素释放激素受体激动剂)

治疗领域

其他疾病肿瘤呼吸系统疾病+ [2]

在研适应症

恶病质厌食症非小细胞肺癌+ [8]

非在研适应症-

原研机构

Ono Pharmaceutical Co., Ltd.

在研机构

Helsinn Healthcare SA

National Cancer Institute

Ono Pharmaceutical Co., Ltd.

非在研机构

Helsinn Therapeutics (U.S.), Inc.

最高研发阶段批准上市

首次获批日期

日本 (2021-01-22),

恶病质

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式C31H43ClN6O3

InChIKeyVFYAEUWJFGTGGO-GHTUPXNNSA-N

CAS号861998-00-7

关联

35

项与盐酸阿拉莫林相关的临床试验

JPRN-jRCTs031230646 / Recruiting临床2期

An exploratory randomized controlled trial of the clinical efficacy of anamorelin hydrochloride in patients after radical surgery for upper gastric cancer and esophagogastric junction cancer - a phase II trial

开始日期2024-02-20

申办/合作机构-

JPRN-jRCTs041230138 / Recruiting临床2期

A randomized controlled trial of Anamorelin to prevent weight loss in post-pancreaticoduodenectomy patients

开始日期2024-02-01

申办/合作机构-

JPRN-jRCTs031230446 / Recruiting临床2期

Prospective, open-label, interventional study to explore the efficacy of the ghrelin agonist anamorelin in patients with cachexia associated with chronic obstructive pulmonary disease

开始日期2023-11-13

申办/合作机构-

100 项与盐酸阿拉莫林相关的临床结果

登录后查看更多信息

100 项与盐酸阿拉莫林相关的转化医学

登录后查看更多信息

100 项与盐酸阿拉莫林相关的专利（医药）

登录后查看更多信息

95

项与盐酸阿拉莫林相关的文献（医药）

2024-02-01·Clinical nutrition (Edinburgh, Scotland)

Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways

Review

作者: Prokopidis, Konstantinos ; Kanatas, Anastasios ; McCullough, Deaglan ; Ispoglou, Theocharis ; Windle, Angela ; Burke, Dermot ; Cox, Natalie ; White, Helen ; Nair, Sherena

Cancer cachexia (CC) syndrome, a feature of cancer-associated muscle wasting, is particularly pronounced in older patients, and is characterised by decreased energy intake and upregulated skeletal muscle catabolic pathways. To address CC, appetite stimulants, anabolic drugs, cytokine mediators, essential amino acid supplementation, nutritional counselling, cognitive behavioural therapy, and enteral nutrition have been utilised. However, pharmacological treatments that have also shown promising results, such as megestrol acetate, anamorelin, thalidomide, and delta-9-tetrahydrocannabinol, have been associated with gastrointestinal and cardiovascular complications. Emerging evidence on the efficacy of probiotics in modulating gut microbiota also presents a promising adjunct to traditional therapies, potentially enhancing nutritional absorption and systemic inflammation control. Additionally, low-dose olanzapine has demonstrated improved appetite and weight management in older patients undergoing chemotherapy, offering a potential refinement to current therapeutic approaches. This review aims to elucidate the molecular mechanisms underpinning CC, with a particular focus on the role of anorexia in exacerbating muscle wasting, and to propose pharmacological and non-pharmacological strategies to mitigate this syndrome, particularly emphasising the needs of an older demographic. Future research targeting CC should focus on refining appetite-stimulating drugs with fewer side-effects, specifically catering to the needs of older patients, and investigating nutritional factors that can either enhance appetite or minimise suppression of appetite in individuals with CC, especially within this vulnerable group.

2023-12-01·Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer

Article

作者: Onda, Shinji ; Okui, Norimitsu ; Furukawa, Kenei ; Tsunematsu, Masashi ; Ikegami, Toru ; Ishizaki, Shunta ; Matsumoto, Michinori ; Shirai, Yoshihiro ; Uwagawa, Tadashi ; Haruki, Koichiro

PURPOSE:

Anamorelin, a selective ghrelin receptor agonist, has been approved for pancreatic cancer treatment in Japan. We aimed to investigate whether systemic inflammation, represented by the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and C-reactive protein (CRP)-albumin ratio (CAR), could predict the effect of anamorelin in patients with advanced pancreatic cancer.

METHODS:

This study included 31 patients who had received anamorelin for advanced pancreatic cancer between 2021 and 2023. Patients' NLR, PLR, LMR, and CAR were evaluated before anamorelin administration. The patients were classified as responders and non-responders based on whether they gained body weight after 3 months of anamorelin administration. We investigated the association between systemic inflammation and anamorelin efficacy using a univariate analysis.

RESULTS:

Twelve (39%) patients were non-responders. A high serum CRP level (p = 0.007) and high CAR (p = 0.013) was associated with non-response to anamorelin. According to the receiver operating characteristics analysis, the CAR cutoff value was 0.06, and CAR ≥ 0.06 was a risk factor (odds ratio, 5.6 [95% confidence interval 1.2-27.1], p = 0.032) for non-response to anamorelin.

CONCLUSION:

CAR can be a predictor of non-response to anamorelin in patients with advanced pancreatic cancer, suggesting the importance of a comprehensive assessment of the inflammatory status.

2023-11-01·Asia-Pacific journal of oncology nursing

The role of pharmacists in multimodal cancer cachexia care

Review

作者: Yamada, Yunami ; Suzuki, Akio ; Fujii, Hironori ; Iihara, Hirotoshi

Cancer cachexia is a complex syndrome, and multidisciplinary management has the potential to improve patient outcomes and efficiency of care. Multidisciplinary management consists primarily of exercise, nutrition, and pharmacotherapy. The pharmacist's role in cancer cachexia is to contribute to appropriate pharmacotherapy practices. For example, anamorelin is an oral drug with ghrelin-like effects that may improve the pathogenesis of cancer cachexia by stimulating appetite and increasing food intake and body weight. Many patients with cancer cachexia are under treatment with anticancer agents, and pharmacists need to determine whether symptoms such as anorexia and nausea are due to cancer cachexia or anticancer agents. Based on that determination, they are then expected to suggest supportive care to the physician. Provision of multidisciplinary care for cancer cachexia requires communication with not only physicians but also with nurses, dietitians, and other professionals so that nutritional therapy can be provided at the time cachexia is detected. However, the role of pharmacists in the management of cancer cachexia is not well established, and there is no evidence that pharmacist interventions are of benefit to patients. In this article, to contribute to the treatment of cancer cachexia by multidisciplinary care, we describe the role of pharmacists in cancer cachexia as currently practiced at our hospital. We also consider future challenges to this type of multidisciplinary care. Evidence concerning multidisciplinary treatment of cancer cachexia is scarce, including therapeutic agents, and there is a current lack of collaboration among medical professionals and education in cancer cachexia. Solving these problems will require efforts in the practice and evaluation of treatment for cancer cachexia.

8

项与盐酸阿拉莫林相关的新闻（医药）

2024-05-10

·CPHI制药在线

24亿美元！小野制药收购Deciphera，加码肿瘤治疗领域

关注并星标CPHI制药在线4月29日，小野制药（ONO Pharmaceutical）宣布以25.6美元/股的价格收购Deciphera Pharmaceuticals，收购总价为24亿美元（173.5亿元），较上周五收盘溢价75%。预计交易将在7月至9月完成，届时Deciphera将成为小野制药全资子公司。这项交易将以全现金形式进行。受并购消息影响，Deciphera盘中大涨72.56%。图片来源：小野制药官网对于小野制药来说，这笔交易提供了一种既可以发展癌症研究方向又能在其他市场获得更强有力立足点的方法。该公司首席执行官Gyo Sagara在一份声明中指出，收购Deciphera将强化小野制药在肿瘤学领域的布局，并加快其在美国和欧洲的业务发展活动。去年以来，小野制药已经三次出手重金加码肿瘤治疗领域。包括： 1. 与计算生物学公司Turbine达成合作，Turbine将应用其端到端、可解释的细胞模拟技术Simulated Cell™ 平台，在计算中发现潜在治疗开发的新靶点，从而推动小野制药肿瘤产品线的扩展。 2. 与Macomics达成药物发现合作，以发现并开发用于癌症治疗的巨噬细胞靶向抗体疗法。根据协议条款，Macomics将利用ENIGMACTM巨噬细胞药物发现平台，针对新靶点识别、表征并开发候选抗体。小野制药将获得候选抗体的全球独家权利，以进行后续开发和商业化。 3. 与德国研究机构BioMed X展开了一项新的癌症免疫疗法联合研究项目，该研究项目的目标是通过利用嗜中性粒细胞的抗肿瘤效应设计下一代免疫疗法。 Deciphera管线中的潜力股们 Deciphera是一家位于马萨诸塞州沃尔瑟姆市的临床阶段生物制药公司，致力于通过解决耐药性的关键机制来改善癌症患者的生活。Deciphera利用其专有的激酶开关控制抑制剂平台来开发高度选择性，有效的小分子候选药物。Deciphera利用对激酶生物学的深刻理解以及专有的化学文库，有目的地设计将激酶维持在"关闭"或失活构象的化合物，这些候选药物可直接抑制与癌症的生长和扩散有关的激酶的活化。 Deciphera Pharmaceuticals首发管线Ripretinib已经在美国、欧洲、中国等40多个国家获批上市，用于四线治疗胃肠间质瘤（GIST）。Ripretinib在2023年实现1.6亿美元销售额，并正在向二线治疗拓展。Ripretinib是一种口服激酶开关抑制剂，目前还将其开发用于治疗晚期全身性肥大细胞增多症（ASM），神经胶质瘤和其他由KIT或PDGFRα激酶诱发的实体瘤等疾病。2019年6月，再鼎医药引进Ripretinib的大中华区权益，支付对价为2000万美元预付款+1.85亿美元里程碑金额，以及一定比例的销售分成。 Ripretinib之外，Deciphera还拥有CSF-1R抑制剂、ULK抑制剂、pan-RAF抑制剂、pan-KIT抑制剂、GCN2激活剂等多种研发管线，包括vimseltinib、DCC-3116（一种ULK抑制剂）以及多个其他的肿瘤学候选药物。Deciphera管线（图片来源：Deciphera Pharmaceuticals官网） Vimseltinib是一款在研、强效、具高选择性的口服CSF1R激酶抑制剂，通过利用调节激酶构象激活的开关控制区的独特特征来选择性和有效地抑制CSF1R，用于治疗腱鞘巨细胞瘤（3期）、色素沉着的绒毛结节性滑膜炎（3期）和实体瘤（2期）等。去年10月，Deciphera公布了vimseltinib在腱鞘巨细胞瘤 (TGCT) 患者中开展的关键3期MOTION研究的积极结果，使用vimseltinib治疗的ORR 出现了统计学上显着且具有临床意义的改善。在意向治疗 (ITT) 人群中，vimseltinib 组在第 25 周的 ORR 为 40%，安慰剂组为 0%（p<0.0001）。同时Deciphera还公布了一项国际、多中心、开放标签的1/2期研究的最新结果，该研究评估了vimseltinib对TGCT患者的安全性和有效性，结果显示：在安全性上，使用vimseltinib治疗耐受性良好，与先前披露的数据一致。没有胆汁淤积性肝毒性的证据。Deciphera预计在今年第二季度向美国FDA递交新药申请（NDA），并在今年第三季度向欧盟递交上市许可申请（MAA）。目前全球仅第一三共pexidartinib这一款CSF-1R抑制剂获批了TGCT适应症，虽然带来了新的治疗方案，但pexidartinib具有严重的肝毒性并被列入黑框警告。因此，临床上仍然需要新一代安全性更高的CSF-1R抑制剂，vimseltinib则有望成为pexidartinib的me-better品种。 DCC-3116是Deciphera公司开发的一款选择性的小分子ULK1/2激酶抑制剂，旨在通过抑制负责启动自噬的ULK1/2激酶来抑制癌症自噬，从而影响肿瘤细胞的存活。DCC-3116是潜在的选择性ULK1/2抑制剂的FIC药物，也是目前该靶标唯一的临床药物。2022年ESMO会议上，公布了一项DCC-3116单药活性的临床数据。结果显示，DCC-3116单药在结直肠癌、胰腺癌等多种携带不同KRAS亚型突变的瘤种中具有初步的临床迹象，部分患者实现了疾病稳定。Deciphera公司希望在今年晚些时候能够确定用于2期临床试验的给药剂量。小野制药肿瘤领域布局小野制药（Ono Pharmaceutical）是日本一家专注于肿瘤学、免疫学、神经病学和专业研究领域的制药公司。目前，小野制药已经上市的药物包括注射、口服和贴片三类。其中注射抗癌药物包括PD-1 Opdivo、治疗多发性骨髓瘤的Kyprolis（卡非佐米）、针对化疗后呕吐的Proemend（fosaprepitant）等。 PD-1基因是由日本京都大学本庶佑教授团队于1992年通过消减杂交技术首次发现，1996~2016年期间，小野制药与本庶佑教授共同申报了8项相关专利。期间，小野制药与美国制药公司Medarex联合开发PD-1抑制剂，而Medarex后期又被BMS收购；故随着纳武单抗在日本（2014年7月）、美国（2014年12月）、欧洲（2015年6月）、中国（2018年6月）的获批，市场销售分别由小野制药负责日本地区，BMS负责美国、欧洲和中国地区。据BMS 2023年财报，O药全球销售额为90亿美元，再加上小野制药在日本的10亿美元，总计超过100亿美元。口服抗癌药物有BTK抑制剂Velexbru（tirabrutinib hydrochloride）、BRAF抑制剂Braftovi（encorafenib）和MEK抑制剂Mektovi（binimetinib）、针对化疗引起的恶心呕吐的Emend（阿瑞匹坦）以及癌症恶病质的Adlumiz（anamorelin）。小野制药肿瘤管线图片来源：只投BioTech 目前在小野制药的肿瘤管线中，既有着TIGIT、LAG-3、BTK、CD47这些热门肿瘤靶点，也有着ILT-4、EP4、MALT1这些新型靶点。整体研发策略一方面以O药为基础的免疫联合治疗在多癌种探索，另一方面在可成药新靶点持续挖掘潜力。参考来源 1. 各公司官网 2. 智慧芽新药科讯【智药研习社近期线下课程预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

免疫疗法并购引进/卖出

2024-02-13

·BioSpace

Yinuoke publication demonstrates a new orally delivered molecule that reverses cancer cachexia and increases survival using in vivo models

Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients announced today the publication of a manuscript in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle demonstrating the effectiveness of a new compound in alleviating cachexia and increasing the survival of tumor-bearing mice in a T-cell dependent manner. Cancer cachexia, a devastating tumor-induced immune disorder leading to body wasting and reduced tolerability to therapeutics, occurs in 80% of all cancer patients and causes 25% of deaths. Previous attempts to treat cachexia have failed due to lack of efficacy in stabilizing patient weight and strength. Yinuoke treats cachexia as a tumor-driven autoimmune disorder rather than a metabolic condition. YNK105 reduces systemic inflammation without the toxic side effects caused by NSAIDS that limit its use. The data shows a significant improvement in cachexigenic tumor-bearing mice in overall survival, increases in body, fat, and muscle weight, and reductions in plasma IL-6 and tissue- derived Stat3. Most impressively, cachectic mice achieved a 100% survival rate with a combination treatment of YNK105 and chemotherapy. “This research is the first demonstration that severe cachexia can be halted and reversed”, said Dr. Lingbing Zhang, founder and CEO of Yinuoke. “The ability to reverse cachexia expands the options for late-stage cancer patients to extend survival and live a higher quality of life. Reversing cachexia requires modulating the immune system’s inflammatory response for longer than an NSAID will allow. We identified R-ketorolac as a potential treatment for cachexia and now have significant evidence to support a superior efficacy and safety pro to current approaches using GDF-15 inhibitors or Anamorelin.” “YNK105 has the potential to be a breakthrough treatment for cancer cachexia that I am excited to bring into the clinic,” said Dr. Andrew Hendifar of Cedars-Sinai. “Pancreatic cancer patients are highly susceptible to cachexia and treatment outcomes are severely impacted. Getting control of cachexia is critical for overall survival of patients with pancreatic cancer and especially for stage 4 and late diagnosed patients. These early studies support moving this program into clinical trials.” The research appearing in the February 1st issue of the Journal of Cachexia, Sarcopenia and Muscle is led by Dr. Martina Schweiger and a team of scientists at the Institute of Molecular Biosciences, University of Graz, Austria. About Yinuoke Yinuoke is on a mission to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable lifelong condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@yinuokeus.com.

临床结果

2023-08-03

·Pharmaceutical Technology

Taiho Oncology and Taiho Pharmaceutical gain FDA approval for Lonsurf

Lonsurf has been approved to treat adult patients with metastatic colorectal cancer. Credit: crystal light / Shutterstock.com. Taiho Oncology and Taiho Pharmaceutical have received approval from the US Food and Drug Administration (FDA) for Lonsurf to treat adult patients with metastatic colorectal cancer (mCRC). The approval is intended for using Lonsurf either as a single agent or with bevacizumab in patients previously treated with oxaliplatin, fluoropyrimidine and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type [without mutations], with an anti-EGFR therapy. Recommended Reports Reports LOA and PTSR Model - Anamorelin Hydrochloride in Chemotherapy Effects GlobalData Reports Innovation in Pharmaceuticals: Pancreatic extract-based compositions GlobalData View all Companies Intelligence Taiho Pharmaceutical Co Ltd Taiho Oncology Inc SUN LIGHT CORPORATION View all Taiho Pharmaceutical discovered and developed Lonsurf, an oral nucleoside antitumour agent. It contains trifluridine, a nucleoside analogue based on thymidine, along with tipiracil, an inhibitor of thymidine phosphorylase (TP). This combination enhances exposure to trifluridine by inhibiting its metabolism by TP. Based on data from the Phase III SUNLIGHT study, the FDA granted approval for the combination of Lonsurf and bevacizumab. This combination showed improvements in progression-free survival and overall survival in patients with mCRC after disease progression or who could not tolerate two previous chemotherapy regimens. These results were compared to the outcomes using LONSURF alone. Taiho Oncology president and CEO Timothy Whitten stated: “The treatment of advanced colorectal cancer has been a core focus of our work at Taiho Oncology since our inception and with good reason: approximately 22% of patients with colorectal cancer in the US are diagnosed after the cancer has metastasised. “The FDA approval of Lonsurf in combination with bevacizumab is another example of how we are continuing to advance care in this disease and provide new hope to patients and their families.”

上市批准临床结果临床3期

100 项与盐酸阿拉莫林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08856	盐酸阿拉莫林	V03	DB06645

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
恶病质	日本	Ono Pharmaceutical Co., Ltd.	2021-01-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
厌食症	申请上市	欧盟	Helsinn Therapeutics (U.S.), Inc.	2015-11-07
非小细胞肺癌	申请上市	欧盟	Helsinn Therapeutics (U.S.), Inc.	2015-11-07
晚期非小细胞肺癌	临床3期	美国	National Cancer Institute	2018-11-27
晚期胰腺腺癌	临床2期	美国	Helsinn Healthcare SA	2023-04-01
胰腺继发性恶性肿瘤	临床2期	美国	Helsinn Healthcare SA	2023-04-01
晚期癌症	临床2期	美国	National Cancer Institute	2017-02-08
晚期恶性实体瘤	临床2期	美国	National Cancer Institute	2017-02-08
疲劳	临床2期	美国	National Cancer Institute	2017-02-08
转移性实体瘤	临床2期	美国	National Cancer Institute	2017-02-08
复发性实体肿瘤	临床2期	美国	National Cancer Institute	2017-02-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04021706 (CTgov)	临床1期	代谢性骨病 \| 肌肉减少症	32	Anamorelin Hydrochloride (Anamorelin)	餘鬱鹹選構醖窪窪夢鏇(構鹽壓餘憲餘製憲衊餘) = 淵廠鹹窪餘顧觸簾襯願鑰鬱獵顧願膚蓋齋鑰鬱 (襯醖艱願顧選製範廠鏇, 壓艱觸衊衊蓋淵獵繭範 ~ 簾獵鬱襯夢鹹選膚觸觸) 更多	-	2024-03-27
				Placebo (Microcrystaline Cellulose)	餘鬱鹹選構醖窪窪夢鏇(構鹽壓餘憲餘製憲衊餘) = 齋夢觸蓋鹹襯艱廠構構鑰鬱獵顧願膚蓋齋鑰鬱 (襯醖艱願顧選製範廠鏇, 齋糧艱醖齋範廠襯蓋繭 ~ 鏇網膚廠遞壓網獵構築) 更多
ESMO_ASIA2023	N/A	不可切除的非小细胞肺癌	73	Anamorelin hydrochloride	襯鑰夢構鹽顧憲壓積襯(鏇築衊鬱簾製膚獵衊顧) = Hyperglycemia should be noted as one of frequent adverse events 衊繭廠醖餘廠獵齋顧鑰 (夢蓋窪蓋窪網醖壓蓋廠 ) 更多	-	2023-12-02
Ono-7643-05 (ESMO_ASIA2023)	N/A	恶病质 \| 胰腺癌 Glasgow prognostic score (GPS)	110	Anamorelin	網鬱膚淵積積築餘構蓋(鏇艱網餘艱積窪鬱遞獵) = The main AEs were gastrointestinal disorders such as nausea and vomiting 選膚淵襯網糧製構膚鹽 (齋鏇繭積鏇積鑰顧壓鹽 ) 更多	-	2023-12-02
ESMO_ASIA2023	N/A	非小细胞肺癌	68	Anamorelin	窪膚襯齋醖蓋繭糧積齋(築醖遞壓繭艱鹽積獵顧) = 3 patients 網遞醖繭廠夢壓繭廠窪 (餘窪鏇顧醖觸鬱積廠構 ) 更多	-	2023-12-02
SCALA-2 (ESMO2023) 人工标引	临床3期	恶病质 \| 非小细胞肺癌	636	Anamorelin 100 mg	襯膚膚餘夢簾蓋膚艱構(獵衊網蓋蓋窪窪窪衊鏇) = Changes of 5-IASS scores for anamorelin versus placebo were not significantly different in both studies 築繭鹽範鑰顧積齋積鑰 (鏇蓋壓築鑰鏇鹹築鹽繭 )	积极	2023-10-20
				placebo
ASCO_GI2023	N/A	结直肠癌	103	anamorelin (Gastric cancer)	製淵衊糧壓顧繭艱鏇膚(觸衊壓簾鹹築衊選憲鑰) = 遞壓鏇顧衊範淵糧淵顧窪齋窪願醖齋憲簾壓觸 (衊顧襯遞憲顧觸糧廠鹽 )	-	2023-01-24
				anamorelin (Pancreatic cancer)	製淵衊糧壓顧繭艱鏇膚(觸衊壓簾鹹築衊選憲鑰) = 蓋鹽範顧鏇觸鹹築製鏇窪齋窪願醖齋憲簾壓觸 (衊顧襯遞憲顧觸糧廠鹽 )
NCT01387282 \| NCT01387269 (ROMANA 1 and 2, ASCO2022)	临床3期	恶病质 \| 非小细胞肺癌	-	Anamorelin	繭積醖襯艱簾糧簾積鏇(夢廠鏇顧鏇鹹齋夢糧鏇) = 顧觸願簾餘醖淵壓蓋遞築膚淵壓構繭鹹簾壓鹹 (壓簾夢夢範願構窪齋獵 ) 更多	积极	2022-06-02
				Placebo	繭積醖襯艱簾糧簾積鏇(夢廠鏇顧鏇鹹齋夢糧鏇) = 鹽積遞襯鏇選築憲膚憲築膚淵壓構繭鹹簾壓鹹 (壓簾夢夢範願構窪齋獵 ) 更多
NCT03035409 (CTgov)	临床2期	复发性实体肿瘤 \| 疲劳 \| 转移性实体瘤 ... 更多	129	Anamorelin	膚製積糧蓋醖夢願艱糧(鏇獵鑰獵顧築夢願蓋衊) = 鹽衊壓衊壓窪廠簾鹹膚蓋築壓壓製窪鑰壓簾窪 (淵衊鹽製膚衊壓觸膚餘, 構繭鹹壓膚鑰襯廠憲願 ~ 窪糧鏇選鹽夢艱簾鑰觸) 更多	-	2022-02-03
NCT01387269 (ROMANA 1, ESMO2018)	临床3期	恶病质 \| 非小细胞肺癌	477	Anamorelin 100mg	鏇夢獵餘鹽鑰顧憲齋鑰(餘鑰廠襯夢範壓憲遞憲) = 鬱糧遞積鑰鬱積艱築襯築願繭範網衊鬱構糧襯 (膚淵鏇蓋蓋遞製餘壓製 ) 更多	-	2018-10-22
NCT01387282 \| NCT01395914 \| NCT01387269 (ROMANA 3, Pubmed \| Ann Oncol) 人工标引	临床3期	恶病质 \| 非小细胞肺癌	513	anamorelin	製構積鹽鏇膚鏇廠夢膚(製膚壓艱艱齋簾顧餘衊) = 窪鹽鹽夢鬱鑰簾積壓餘顧製選築鬱窪淵遞齋觸 (積餘廠構顧淵壓壓製築 ) 更多	积极	2017-08-01
				Placebo	製構積鹽鏇膚鏇廠夢膚(製膚壓艱艱齋簾顧餘衊) = 築憲獵夢製選淵糧醖簾顧製選築鬱窪淵遞齋觸 (積餘廠構顧淵壓壓製築 ) 更多